89Bio Inc (ETNB)

Jan 13, 2025, 6:08 PM EST - 7 days ago

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

Dec 19, 2024, 4:05 PM EST - 4 weeks ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 15, 2024, 8:05 AM EST - 2 months ago

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Nov 12, 2024, 11:58 PM EST - 2 months ago

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2024, 4:01 PM EST - 2 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 5, 2024, 4:05 PM EST - 2 months ago

89bio to Participate in the UBS Global Healthcare Conference

Oct 15, 2024, 8:30 AM EDT - 3 months ago

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

Sep 30, 2024, 4:05 PM EDT - 4 months ago

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

Sep 16, 2024, 4:05 PM EDT - 4 months ago

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

Aug 7, 2024, 1:59 PM EDT - 5 months ago

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 7, 2024, 8:00 AM EDT - 5 months ago

89bio Appoints Francis Sarena as Chief Operating Officer

Aug 5, 2024, 4:05 PM EDT - 6 months ago

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

May 23, 2024, 6:32 AM EDT - 8 months ago

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 22, 2024, 4:05 PM EDT - 8 months ago

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

May 14, 2024, 8:00 AM EDT - 8 months ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

May 9, 2024, 4:05 PM EDT - 9 months ago

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:05 PM EDT - 9 months ago

89bio to Participate in the BofA Securities 2024 Health Care Conference

May 2, 2024, 4:05 PM EDT - 9 months ago

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

Apr 17, 2024, 4:05 PM EDT - 9 months ago

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Mar 27, 2024, 8:00 AM EDT - 10 months ago

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Mar 12, 2024, 8:00 AM EDT - 11 months ago

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

Mar 8, 2024, 4:05 PM EST - 11 months ago

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2024, 4:05 PM EST - 11 months ago

89bio to Participate in the Leerink Partners Global Biopharma Conference

Feb 29, 2024, 4:05 PM EST - 11 months ago

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Feb 6, 2024, 4:05 PM EST - 1 year ago

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 12, 2023, 7:30 AM EST - 1 year ago

89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 7, 2023, 7:00 AM EST - 1 year ago

89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Dec 6, 2023, 6:59 PM EST - 1 year ago

89bio: Despite Peer Trial Setback, Potential Remains In NASH

Dec 4, 2023, 7:00 AM EST - 1 year ago

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024

Nov 27, 2023, 8:00 AM EST - 1 year ago

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

Nov 21, 2023, 4:01 PM EST - 1 year ago

89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference

Nov 12, 2023, 12:15 PM EST - 1 year ago

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

Nov 8, 2023, 4:01 PM EST - 1 year ago

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Oct 26, 2023, 2:15 PM EDT - 1 year ago

89bio's Low Price Presents An Opportunity

Oct 17, 2023, 8:00 AM EDT - 1 year ago

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

Sep 21, 2023, 8:00 AM EDT - 1 year ago

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

Sep 20, 2023, 8:00 AM EDT - 1 year ago

89bio to Participate in the 2023 Cantor Global Healthcare Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 1:48 PM EDT - 1 year ago

89bio, Inc.: A Big Bet On NASH

Aug 9, 2023, 4:01 PM EDT - 1 year ago

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 26, 2023, 3:21 PM EDT - 1 year ago

Weight-loss drugs in development aim to replace injections with pills

AKRO LLY MDGL NVO PFE VRTX

Jun 24, 2023, 5:05 AM EDT - 1 year ago

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

Jun 24, 2023, 5:01 AM EDT - 1 year ago

Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

Jun 13, 2023, 8:29 AM EDT - 1 year ago

89bio shares rise as analysts see improved outlook for NASH treatments

Jun 7, 2023, 8:00 AM EDT - 1 year ago

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

May 28, 2023, 4:18 AM EDT - 1 year ago

89bio: Great Prospects After Excellent Phase 2 Data

May 23, 2023, 8:00 AM EDT - 1 year ago

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

May 4, 2023, 4:05 PM EDT - 1 year ago

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 8:00 AM EDT - 1 year ago

89bio to Participate in Upcoming Investor Conferences

Mar 29, 2023, 11:40 PM EDT - 1 year ago

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

AKRO ICPT LLY MDGL NVO PFE TERN